NeuroCores, Inc.’s cover photo
NeuroCores, Inc.

NeuroCores, Inc.

Biotechnology Research

Boston, MA 120 followers

A biotech company unlocking hope for patients with rare pediatric diseases.

About us

NeuroCores Inc. is a preclinical-stage biopharmaceutical company focused on developing treatments for rare pediatric neurological disorders and neurodegenerative diseases. The Company’s lead product candidate, KIT-13, is undergoing nonclinical studies for Rett Syndrome and other neurodegenerative diseases, and it has been granted both Rare Pediatric Drug Designation and Orphan Drug Designation from the US FDA for treating Rett syndrome. Additionally, NeuroCores has two more compounds, KIT-18 and KIT-20, for RCDP and Leigh Disease, respectively. NeuroCores's innovative plasmalogen derivatives have the potential to treat many more CNS disorders because of their potent anti-neuroinflammatory and neurogenesis effects.

Website
www.neurocores.com
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Boston, MA
Type
Privately Held

Locations

Employees at NeuroCores, Inc.

Updates

Similar pages

Browse jobs